Neuro Event Labs Receives FDA 510(k) Clearance for the Nelli® Seizure Monitoring System — Hadean…
Continue Reading-
Step Pharma announces completion of €38 million Series C financing
Step Pharma announces completion of €38 million Series C financing — Hadean Ventures Home Portfolio…
Continue Reading -
Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy secondary to AMD
Complement Therapeutics Receives FDA IND Clearance...
Continue Reading -
Ribbon Bio and Scala Biodesign into Powerful Partnership Focused on Customers
Ribbon Bio and Scala Biodesign into Powerful Partnership Focused on Customers — Hadean Ventures Home…
Continue Reading -
ARTHEx Biotech Upsizes Series B Financing Round to $87M to Advance Lead Program ATX-01 in Myotonic Dystrophy Type 1 and Expand Pipeline of Targeted RNA Medicines
ARTHEx Biotech Upsizes Series B Financing Round to $87M...
Continue Reading -
Gesynta Pharma Announces Second Closing of Series B Now Totaling SEK 347m – HealthCap and Hadean Growth Fund Join Strong Investor Syndicate
Gesynta Pharma Announces Second Closing of Series B Now Totaling SEK 347m – HealthCap and…
Continue Reading -
SAGA Diagnostics® Announces Medicare Coverage for Pathlight™ MRD Test in Breast Cancer Across All Subtypes
SAGA Diagnostics® Announces Medicare Coverage for Pathlight™ MRD Test in Breast Cancer Across All Subtypes…
Continue Reading -
Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases
Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal…
Continue Reading -
Ribbon Bio and Syngoi Technologies Commence Strategic Collaboration to Advance Gene Therapies with Synthetic DNA
Ribbon Bio and Syngoi Technologies Commence Strategic Collaboration to Advance Gene Therapies with Synthetic DNA…
Continue Reading -
Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period
Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of…
Continue Reading